The matrix metalloproteinases as pharmacological target in osteoarthritis: Statins may be of therapeutic benefit

Medical Hypotheses

Volumn 69, Issue 3, 2007, Pages 557-559

  Wu, Yin Song ^a   Hu, Yun Yu ^a   Yang, Rui Fu ^a   Wang, Zhen ^a   Wei, Yi Yong ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MATRIX METALLOPROTEINASE;

ARTICLE; CARTILAGE CELL; CARTILAGE DEGENERATION; DISEASE COURSE; DRUG EFFECT; ENZYME ACTIVITY; ENZYME RELEASE; HUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN SECRETION;

ATHEROSCLEROSIS; CARTILAGE; DISEASE PROGRESSION; ENZYME INHIBITORS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION; MATRIX METALLOPROTEINASES; MODELS, BIOLOGICAL; OSTEOARTHRITIS;

EID: 34447285775     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2007.01.042     Document Type: Article

References (17)

1. Brandt K.D., and Mazzuca S.A. Lessons learned from nine clinical trials of disease-modifying osteoarthritis drugs. Arthritis Rheum 52 (2005) 3349-3359
2. Tanaka S., Hamanishi C., Kikuchi H., and Fukuda K. Factors related to degradation of articular cartilage in osteoarthritis: a review. Semin Arthritis Rheu 27 (1998) 392-399
3. Mandelbaum B., and Waddell D. Etiology and pathophysiology of osteoarthritis. Orthopedics 28 (2005) s207-s214
4. Arner E.C., Hughes C.E., Decicco C.P., Caterson B., and Tortorella M.D. Cytokine-induced cartilage proteoglycan degradation is mediated by aggrecanase. Osteoarthritis and cartilage/OARS. Osteoarthritis Res Soc 6 (1998) 214-228
5. Iannone F., and Lapadula G. The pathophysiology of osteoarthritis. Aging-Clin Exp Res 15 (2003) 364-372
6. Ghosh P. The pathobiology of osteoarthritis and the rationale for the use of pentosan polysulfate for its treatment. Semin Arthritis Rheu 28 (1999) 211-267
7. Endo A. The discovery and development of HMG-CoA reductase inhibitors. J Lipid Res 33 (1992) 1569-1582
8. Dollery C.M., McEwan J.R., and Henney A.M. Matrix metalloproteinases and cardiovascular disease. Circ Res 77 (1995) 863-868
9. Bellosta S., Via D., Canavesi M., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscl Throm Vas 18 (1998) 1671-1678
10. Corsini A., Bellosta S., Baetta R., Fumagalli R., Paoletti R., and Bernini F. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Therapeut 84 (1999) 413-428
11. Luan Z., Chase A.J., and Newby A.C. Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages. Arterioscl Throm Vas 23 (2003) 769-775
12. Thunyakitpisal P.D., and Chaisuparat R. Simvastatin, an HMG-CoA reductase inhibitor, reduced the expression of matrix metalloproteinase-9 (Gelatinase B) in osteoblastic cells and HT1080 fibrosarcoma cells. J Pharmacol Sci 94 (2004) 403-409
13. Lazzerini P.E., Capecchi P.L., Nerucci F., et al. Simvastatin reduces MMP-3 level in interleukin 1beta stimulated human chondrocyte culture. Ann Rheum Dis 63 (2004) 867-869
14. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., and Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 103 (2001) 926-933
15. Fukumoto Y., Libby P., Rabkin E., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation 103 (2001) 993-999
16. Klareskog L., and Hamsten A. Statins in rheumatoid arthritis-two birds with one stone?. Lancet 363 (2004) 2011-2012
17. Kantola T., Kivisto K.T., and Neuvonen P.J. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 64 (1998) 177-182